Archive | February, 2014

Hot Life Science Investor Mandate 2: Venture Capital Firm Seeking Therapeutics for Blood Diseases

6 Feb

A venture capital firm based in the Western United States recently raised a $50M fund with a specific focus in blood-related therapeutics and technologies. The firm can allocate up to $10M per company depending on the financial needs of the company. The firm will consider companies located worldwide. The firm is actively seeking new investment opportunities.

The firm is currently looking to invest in regenerative medicine with particular interest in therapeutics for blood diseases and blood-related technologies/products. The firm is particularly interested in cord blood stem cells and the regeneration of red blood cells. The firm will invest in products in early clinical (Phase I) through Phase III of clinical trials. 

The firm seeks companies with an experienced management teams or technical experts in the relevant technology.

Hot Life Science Investor Mandate 3: CRO Corporate Venture Seeking Opportunities Globally

6 Feb

The corporate venture capital arm of a global contract research organization (CRO) has the ability to allocate anywhere from $100,000 to $2 million of equity capital to companies. However, the arm only invests in opportunities where it can leverage its CRO services as a piece of the investment, and as such, looks to tailor its CRO services to the needs of its partners, helping them to reach key value-added milestones. The firm will consider opportunities worldwide, and plans to be involved with 6-10 companies over the next 6-9 months.

The corporate VC is willing to consider making investments into companies developing medical devices, diagnostics, and therapeutics that are able to utilize their parent company’s CRO services to advance their product into or through clinical trials. Currently, they are most interested in companies developing therapeutics and biologics with a lead asset anywhere from 6-9 months pre-IND, to Phase III of clinical trials. The arm is completely opportunistic in terms of subsector and indication, and is willing to consider companies targeting orphan indications.

The corporate VC often acts as a co-investor, and generally does not require a board seat. Despite not being active on the board, the firm is a long-term investor and looks to provide market, development, and regulatory insight and strategic advice into selected companies.